#Stream Biomedical #rhPDVLG3 #ASENT Conference

Stream Biomedical to Present at ASENT 2025

HOUSTON, March 4, 2025 /PRNewswire/ -- Stream Biomedical, Inc. is making headlines with its announcement of an accepted abstract for presentation at the upcoming Annual Meeting of the American Society of Neurotherapeutics (ASENT) Conference scheduled for March 12-14, 2025, in Bethesda, MD. This clinical-stage biotechnology company, renowned for its work in neurodegenerative diseases, will showcase its groundbreaking research on the drug candidate known as recombinant human perlecan domain V laminin-like globulin 3 (rhPDVLG3).

This first-in-class therapy has demonstrated significant promise in preclinical studies, particularly in preventing brain tissue damage following critical conditions such as acute ischemic stroke, traumatic brain injury, and Alzheimer's disease. Dr. William Schwieterman, the CEO of Stream Biomedical, expressed excitement about presenting their innovative findings publicly for the first time. He stated, “We are eager to share our highly promising data for rhPDVLG3, a potent recombinant biologic agent with unique and powerful neuroprotective properties.”

About rhPDVLG3

rhPDVLG3, a synthetic version derived from naturally occurring perlecan domain V LG3, plays a vital role in the body's innate response to neurovascular injury. This protein, released from the vascular basement membrane during hypoxic or traumatic events, has exhibited remarkable capabilities in animal models to repair the blood-brain barrier and facilitate recovery in other brain tissues. Clinical data suggests that when given in higher than normal concentrations post-injury, rhPDVLG3 can effectively promote neurovascular tissue repair, a finding supported by advanced, state-of-the-art 3D imaging techniques.

Looking Ahead

Stream Biomedical is on a mission to revolutionize neurovascular repair with a commitment to developing novel biological therapeutic agents that target a range of acute and chronic neurodegenerative conditions. Their vision includes addressing serious ailments like Alzheimer's disease alongside immediate traumatic brain injuries and strokes. The upcoming ASENT Conference is not only a platform for Stream to present its promising results but also a crucial opportunity to engage with the broader scientific community and explore collaborative avenues for further advancing this groundbreaking research.

In wrapping up his comments, Dr. Schwieterman emphasized his belief in rhPDVLG3’s transformative potential across various Central Nervous System diseases. As the healthcare community eagerly anticipates further developments from Stream Biomedical, their participation at this prestigious conference marks a significant step forward in the fight against debilitating neurodegenerative diseases.

About Stream Biomedical, Inc.
Stream Biomedical, Inc. operates as a virtual biotechnology company based in Houston, Texas. Their focus is on creating innovative therapies that promise to enhance the quality of life for patients suffering from neurodegenerative diseases. With a commitment to advancing scientific understanding and therapeutic options, Stream Biomedical aims to make a lasting impact in the field of neurotherapeutics.

Media Contact:
William